| EN

2023 ESMO:澳门PG电子游戏APP官方网站 Zaiming will showcase latest clinical data regarding 3 three innovative products and 3 pipeline candidates

Release time:2023-10-16

A total of 10 studies present at the upcoming 2023 ESMO

linked-in gif.gif

 

COSELA®(Trilaciclib Hydrochloride for Injection :2 posters

 

Antitumor Activity and Safety Profile of Trilaciclib in Chinese patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) receiving Chemotherapy (TRACES): Updated results from TRACES

Presentation Number:1998P

Speakers :Ying Liu (Changchun, China)

Onsite Poster display date: Saturday, 21 October 2023

1998P.pdf


 

Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: a review on the basis of clinical trials

Presentation Number:2024P

Speakers: Manuel Dómine (Madrid, Spain)

Onsite Poster display date:Saturday, 21 October 2023


 

Envafolimab (subcutaneously injectable PD-L1 antibody):5 posters

Phase Ib/II Trial of Envafolimab, a Novel Subcutaneous Singledomain AntiPDL1 Monoclonal Antibody, Plus Lenvatinib in Patients with Selected Advanced Solid Tumors

Presentation Number:1049P

Speakers:Tianshu Liu (Shanghai, China)

Onsite Poster display date:Monday, 23 October 2023

1049P.pdf

 

Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial

Presentation Number:920P

Speakers :Xiaohui Wang (Guangzhou, China)

Onsite Poster display date:Sunday, 22 October 2023

920P.pdf

 

Combination Therapy of Envafolimab and Suvemcitug in Patients with Hepatocellular Carcinoma (HCC): Results from a Phase II Clinical Trial

Presentation Number:959P

Speakers:Lixia Ma (Changchun, China)

Onsite Poster display date:Monday, 23 October 2023

959P.pdf

 

Combination Therapy of Envafolimab, Suvemcitug, and FOLFIRI in Patients with Metastatic Microsatellite Stable (MSS) or Mismatch-repair Proficient (pMMR) Colorectal Cancer: Results from a Phase II Clinical Trial

Presentation Number:636P

Speakers:Ying Liu (ChangChun, China)

Onsite Poster display date:Sunday, 22 October 2023

636P.pdf

 

Combination Therapy of Envafolimab and Suvemcitug with chemotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC): Results from a Phase II Clinical Trial

Presentation Number:1467P

Speakers :Chunjiao Wu (Changchun, China)

Onsite Poster display date:Monday, 23 October 2023

1467P.pdf

 

Endostar®(Recombinant Human Endostatin):1 poster

Phase II trial of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus

Presentation Number:1545P

Speakers:Yuexiao Qi (Lanzhou, China)

Onsite Poster display date:Monday, 23 October 2023

 

 

Suvemcitug(VEGF mAb:3 posters

Combination Therapy of Envafolimab and Suvemcitug in Patients with Hepatocellular Carcinoma (HCC): Results from a Phase II Clinical Trial

Presentation Number:959P

Speakers:Lixia Ma (Changchun, China)

Onsite Poster display date:Monday, 23 October 2023

959P.pdf

 


Combination Therapy of Envafolimab, Suvemcitug, and FOLFIRI in Patients with Metastatic Microsatellite Stable (MSS) or Mismatch-repair Proficient (pMMR) Colorectal Cancer: Results from a Phase II Clinical Trial

Presentation Number:636P

Speakers:Ying Liu (Changchun, China)

Onsite Poster display date:Sunday, 22 October 2023

636P.pdf

 

Combination Therapy of Envafolimab and Suvemcitug with chemotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC): Results from a Phase II Clinical Trial

Presentation Number:1467P

Speakers :Chunjiao Wu (Changchun, China)

Onsite Poster display date:Monday, 23 October 2023

1467P.pdf

 

 

SIM0235 (TNFR2 mAb):1 poster

SIM1811-03 (SIM0235), an anti-tumor necrosis factor receptor-2 (TNFR2) monoclonal antibody, in patients with advanced solid tumor and/or cutaneous T cell lymphomas (CTCL): preliminary results from an on-going first-in-human phase I trial in China

Presentation Number:696P

Speakers:Furong Liu (Guangzhou, China)

Onsite Poster display date:Monday, 23 October 2023

696P.pdf

 

SIM0272 (PRMT5 inhibitor,product code:SCR-6920):1 poster

 

A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of SCR-6920, a Protein Arginine Methyltransferase 5(PRMT5) Inhibitor, in Patients with Advanced Malignant Tumors

Presentation Number:675P

Speakers:Jinming Yu (Jinan, China)

Onsite Poster display date:Monday, 23 October 2023

675P.pdf